<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961529</url>
  </required_header>
  <id_info>
    <org_study_id>271-102-00006</org_study_id>
    <nct_id>NCT03961529</nct_id>
  </id_info>
  <brief_title>Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Open-label, Uncontrolled, Long-term Trialto Demonstrate the Safety and Efficacy of 1% OPA-15406 Ointment in Adult Patients With Atopic Dermatitis and of 0.3% and 1% OPA-15406 Ointments in Pediatric Patients With Atopic Dermatitis (Phase 3 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and
      1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 52</time_frame>
    <description>The number of subjects and incidences are calculated regarding adverse events occurring after IMP administration (treatment-emergent adverse events: TEAEs), TEAEs by severity, TEAEs resulting in death, Serious TEAEs, TEAEs leading to discontinuation of IMP administration, TEAEs in skin and subcutaneous tissue disorders by CTCAE grade, TEAEs at treatment areas and TEAEs by time of onset.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate in Investigator's Global Assessment(IGA)</measure>
    <time_frame>Week 52</time_frame>
    <description>Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Week 52</time_frame>
    <description>Incidence of success in EASI is defined as the rate of subjects whose EASI score has improved at least 90%, 75% or 50% from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.3% OPA-15406 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPA-15406 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% OPA-15406 ointment</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>0.3% OPA-15406 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% OPA-15406 ointment</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>1% OPA-15406 ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: At least 2 years (at time of obtaining informed consent)

          -  Diagnosis of AD based on the Japanese Dermatological Association's criteria

          -  Atopic dermatitis affecting â‰¥5% of body surface area (BSA, excluding scalp) at the
             screening and baseline examinations

        Exclusion Criteria:

        - Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification
        of AD, within 28 days prior to the baseline examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Shirao clinic of pediatrics and pediatric allergy</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

